Aaron Ward, MD
Internal Medicine · Lincoln, NENPI 1245380120
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Dexcom, Inc. at 26.8% of the total. Reporting peaked in 2023 at $8,071 and has fallen 99.8% since, to $16 in 2025. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $56.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$4K
- Senseonics, Incorporated$4K
- Ascensia Diabetes Care US Inc.$3K
- Novo Nordisk$679
- Lilly USA, LLC$583
- AstraZeneca$579
- plus $2K from 32 others
Across 16 payments — averaging $1569.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ionis Pharmaceuticals, Inc.$25K
What the payments were for
- Consulting fees$6,91545%
- Speaking & faculty fees$4,02226%
- Food & beverage$4,20227%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 7 | $4,102 |
| Senseonics, Incorporated | 1 | $4,000 |
| Ascensia Diabetes Care US Inc. | 26 | $3,262 |
| Novo Nordisk | 45 | $679 |
| Lilly USA, LLC | 45 | $583 |
| AstraZeneca(2 entities) | 21 | $579 |
| Amgen(2 entities) | 24 | $356 |
| Corcept Therapeutics | 7 | $159 |
| Sanofi-aventis U.S. LLC | 10 | $147 |
| Abbott | 8 | $142 |
| Medtronic | 7 | $125 |
| Zealand Pharma US, Inc. | 7 | $116 |
| Boehringer Ingelheim | 7 | $112 |
| Tandem Diabetes Care, Inc. | 7 | $106 |
| Mannkind Corporation | 6 | $102 |
| Antares Pharma, Inc. | 4 | $71 |
| Insulet Corporation | 3 | $68 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Amryt Pharma Holdings Ltd | 4 | $56 |
| Valeritas, Inc. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $39 |
| Halozyme Inc | 2 | $34 |
| BETA Bionics, Inc. | 2 | $31 |
| Lifescan, Inc. | 2 | $30 |
| AbbVie | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Radius Health, Inc. | 2 | $26 |
| IBSA Pharma Inc. | 2 | $26 |
| Nevro Corp. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$4,022
- Eversense$4,000
- FARXIGA$143
How this compares
$15,315 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 353 | $394,717 |
| TrulicityDulaglutide | 168 | $210,281 |
| Tresiba Flextouch U-200Insulin Degludec | 154 | $183,787 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 154 | $149,311 |
| JardianceEmpagliflozin | 107 | $121,787 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 94 | $120,982 |
| MounjaroTirzepatide | 99 | $106,531 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 112 | $99,528 |
| Humalog Kwikpen U-200Insulin Lispro | 83 | $89,934 |
| Tresiba Flextouch U-100Insulin Degludec | 150 | $89,429 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 105 | $78,506 |
| FarxigaDapagliflozin Propanediol | 87 | $69,530 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $52,392 |
| Novolog FlexpenInsulin Aspart | 144 | $40,869 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $36,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Xultophy 100-3.6, Novolog | $679 | $462,241424 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $583 | $326,042309 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $112 | $165,649148 claims |
| AstraZenecaFarxiga | $579 | $69,53087 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $147 | $30,46713 claims |
| AbbVieSynthroid | $30 | $2,82942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Lincoln
- Sherri ThomasLincoln$136K
- Anthony RossLincoln$6K
- Wasim ChughtaiLincoln$6K
- Mary DreyLincoln$6K
- Alexander RyanLincoln$5K
- James FosnaughLincoln$3K
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.